Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
October 05, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam)
October 02, 2018 08:00 ET
|
Melinta Therapeutics
Vabomere monotherapy was associated with increased clinical cure, decreased mortality, and was well tolerated compared to best available therapy (BAT) -Data used by CMS in decision to grant a new...
Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries
October 01, 2018 08:15 ET
|
Melinta Therapeutics
- Total consideration of up to $265 million (including potential royalties) -- Expands on existing commercial and co-development agreement for Baxdela® (delafloxacin) - NEW HAVEN, Conn. and FLORENCE,...
Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)
September 21, 2018 07:37 ET
|
Melinta Therapeutics
Recommended to be approved for treatment of: Complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) -Hospital-acquired pneumonia including ventilator associated pneumonia...
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
September 18, 2018 08:52 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference
September 06, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
September 06, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’)Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Discovery Enabled by Discuva Platform and...
Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 29, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
HP Delivers Innovations to Public Health with New CDC Pilot Program
August 27, 2018 11:01 ET
|
HP Inc.
News highlights CDC launches HP pilot program with the purchase of HP BioPrinters for four regional labs in New York, Minnesota, Tennessee, and Wisconsin.HP BioPrinters, with inkjet printing...
Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS
August 03, 2018 13:31 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...